Edition:
United Kingdom

CytRx Corp (CYTR.OQ)

CYTR.OQ on NASDAQ Stock Exchange Capital Market

0.60USD
15 Feb 2019
Change (% chg)

$0.00 (+0.42%)
Prev Close
$0.60
Open
$0.61
Day's High
$0.61
Day's Low
$0.60
Volume
15,893
Avg. Vol
27,435
52-wk High
$2.18
52-wk Low
$0.35

Latest Key Developments (Source: Significant Developments)

CytRx Corp Highlights Positive Results From Phase 2/3 Clinical Trial In Niemann Pick Disease Type C (Npc)
Wednesday, 6 Feb 2019 

Feb 6 (Reuters) - CytRx Corp ::CYTRX CORPORATION HIGHLIGHTS POSITIVE RESULTS FROM FULL DATA SET OF PHASE 2/3 CLINICAL TRIAL IN NIEMANN PICK DISEASE TYPE C (NPC) CONDUCTED BY ARIMOCLOMOL LICENSEE ORPHAZYME A/S.CYTRX CORP - CYTRX ELIGIBLE TO RECEIVE UP TO $120 MILLION IN FUTURE MILESTONES, PLUS ROYALTIES, FROM ARIMOCLOMOL LICENSING AGREEMENT.CYTRX CORP - ORPHAZYME TO ENGAGE WITH FDA AND EMA ON PATH TO APPROVAL WHILE PREPARING FOR FILING.CYTRX CORP - ORPHAZYME COMMUNICATED THAT IT PLANS TO SUBMIT REGULATORY FILING TO FDA AND EMA DURING FIRST HALF OF 2020.CYTRX CORP - IN FULL DATA SET ANALYSIS, TREATMENT WITH ARIMOCLOMOL ADJUNCT TO ROUTINE CLINICAL CARE RESULTED IN A 74% REDUCTION IN DISEASE PROGRESSION.  Full Article

Cytrx Announces $7.0 Million Registered Direct Offering
Friday, 11 May 2018 

CytRx Corp ::CYTRX ANNOUNCES $7.0 MILLION REGISTERED DIRECT OFFERING.CYTRX - ENTERED PURCHASE AGREEMENTS WITH CERTAIN INSTITUTIONAL INVESTORS TO SELL IN REGISTERED DIRECT OFFERING 5.6 MILLION SHARES AT PRICE OF $1.25/SHARE.  Full Article

Cytrx Reports First Quarter Loss Of $0.15 Per Share
Tuesday, 8 May 2018 

May 8 (Reuters) - CytRx Corp ::CYTRX REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS.Q1 LOSS PER SHARE $0.15.CASH AND CASH EQUIVALENTS OF $35.1 MILLION AS OF MARCH 31, 2018.  Full Article

Cytrx reports strategic realignment of clinical development team
Monday, 6 Nov 2017 

Nov 6 (Reuters) - Cytrx Corp ::Cytrx announces strategic realignment of clinical development team.Cytrx - announced ‍strategic realignment of drug development efforts for advancing new drug candidates based on ladr technology platform​.Cytrx Corp - co's drug development, manufacturing and regulatory activities will be led by Hurley Consulting Associates​.Cytrx Corp - ‍is poised to file INDS with FDA for one or more new ladr drug conjugates in 2018​.  Full Article

Cytrx Corp announces reverse stock split
Tuesday, 31 Oct 2017 

Oct 31 (Reuters) - Cytrx Corp :Cytrx Corporation announces reverse stock split.Cytrx Corp- ‍1-for-6 reverse​ stock split will become effective as of commencement of trading on Wednesday, November 1, 2017.  Full Article

Cytrx corp says ‍Nasdaq has granted co's request for a continued listing
Tuesday, 17 Oct 2017 

Oct 16 (Reuters) - Cytrx Corp ::Cytrx corp - ‍Nasdaq has granted co's request for a continued listing pending results of a stockholder vote on or before October 30, 2017​.  Full Article

Cytrx highlights inclusion of aldoxorubicin in pending upcoming clinical trial submissions
Thursday, 12 Oct 2017 

Oct 12 (Reuters) - Cytrx Corp ::Cytrx Corporation highlights inclusion of aldoxorubicin in pending upcoming clinical trial submissions planned by Licensee Nantcell, Inc..  Full Article